CurrentPremera BluecrossPolicy MEDICAL POLICY -8.01.541

Focal Treatments for Prostate Cancer

This policy governs coverage of focal (lesion-targeted) ablative therapies for localized prostate cancer for Premera Blue Cross members, outlining investigational status and coding. It affects providers who perform or request authorization for focal prostate cancer treatments.

Policy Summary

PayerPremera Bluecross

PolicyFocal Treatments for Prostate Cancer

Policy CodePolicy MEDICAL POLICY -8.01.541

Change TypeNo material change

Effective DateMay 1, 2026

Next Review Date

Key ActionDo not request coverage for focal prostate ablation as routine primary therapy; prior authorization is likely required and may be denied unless provided in the context of an eligible clinical trial or special arrangement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

All focal therapiespolicy labels as investigational

5+modalities listed

limited useguideline caution

1ongoing IDE/clinical trials

manyreferences

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Focal Therapies for Localized Prostate Cancer

Investigational / Not covered

Covered when ALL of the following are met

Investigational stance: Use of any focal therapy modality to treat individuals with localized prostate cancer is investigational.

Includes but is not limited to focal laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, radiofrequency ablation (RFA), and photodynamic therapy.

General medical necessity and guideline-aligned limitations

Coverage stance derived from evidence synthesis and guideline recommendations

Primary localized prostate cancer - evidence summary: Focal ablation techniques have insufficient high-quality comparative evidence versus standard treatments (radical prostatectomy, external-beam radiotherapy, or active surveillance) to demonstrate improved net health outcomes; methods and patient selection are not standardized.

Based on systematic reviews, registry and observational studies with heterogeneous reporting, short follow-up, and small sample sizes.

Guideline-based restrictions: Major guideline bodies recommend caution: inform patients about lack of comparative data; do not recommend whole-gland or focal ablation for high-risk disease outside clinical trials; and restrict routine primary use—NICE advises HIFU only with special arrangements for governance, consent, and audit or research.

References: AUA/ASTRO/ASCO/SUO, NCCN, NICE guideline statements.

This policy applies to focal (lesion-targeted) ablative therapies for localized prostate cancer and addresses a range of modalities including focal laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, radiofrequency ablation (RFA), and photodynamic therapy. It governs coverage and coding for these procedures when used to treat individuals with localized prostate cancer and is intended for providers who perform or request authorization for focal prostate treatments. The policy designates use of any focal therapy modality for localized prostate cancer as investigational and therefore not covered under the standard medical necessity criteria.

Major clinical guidelines recommend caution when considering whole-gland or focal ablation as primary therapy. The AUA/ASTRO/ASCO/SUO guidance advises clinicians to inform patients that high-quality comparative data are lacking and states clinicians should not recommend whole gland or focal ablation for patients with high-risk prostate cancer outside of a clinical trial. The NCCN similarly does not recommend cryotherapy or other local ablation as routine primary therapy for localized disease because of insufficient long-term comparative data. NICE recommends that HIFU be used only with special arrangements for governance, consent, and audit or research.

An FDA advisory committee in 2020 voted against recommending approval of the photodynamic agent padeliporfin (Tookad) for localized prostate cancer, expressing concern that men with very low–risk disease might elect this therapy instead of active surveillance given the unproven long-term benefits and harms. This regulatory action is noted as contextual support for the policy’s investigational stance toward photodynamic and other focal therapies.

Consistent with the evidence review, the policy explicitly labels focal treatments for prostate cancer as investigational. Use of any focal therapy modality to treat localized prostate cancer — including but not limited to focal laser ablation, HIFU, cryoablation, RFA, and photodynamic therapy — is designated investigational and excluded from routine coverage.

The available evidence is insufficient to support routine use of focal or whole-gland ablation as primary therapy. Systematic reviews and observational studies are heterogeneous, with short follow-up and small sample sizes, and no prospective comparative evidence demonstrates improved net health outcomes versus established treatments (radical prostatectomy, external-beam radiotherapy, or active surveillance). Methods for lesion selection and treatment extent are not standardized, and comparative functional benefit among focal techniques has not been established.

The FDA advisory committee’s concerns about padeliporfin highlight broader regulatory and clinical uncertainties: specifically, that treating men with very low–risk disease may substitute for active surveillance without proven long-term benefit. The committee’s negative recommendation underscores the lack of definitive evidence on long-term outcomes and supports a cautious, investigational classification for photodynamic and related focal therapies.

Coding and Product Codes

Covered CPT / Procedure CodesCPT

0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance with MR-fused images or other enhanced ultrasound imaging.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed MRI examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0950T	Ablation of benign prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance (new code effective 07/01/25).
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance.
55899	Unlisted procedure, male genital system.

FDA Product Codes / Device Classificationsmixed

LLZ	FDA product code associated with focal laser ablation systems / laser thermal therapy kits used to necrotize or coagulate soft tissue under MRI guidance.
GEX	FDA product code associated with focal laser ablation and related laser therapy devices cleared via 510(k).
FRN	FDA product code linked to laser thermal therapy kits (e.g., Elesta) for interstitial irradiation of soft tissue including urology indications.
GEH	FDA product code for cryoablation devices cleared for prostate cryoablation (e.g., Visual-ICE, CryoCare, IceSphere).
GEI	FDA product code for radiofrequency ablation (RFA) devices cleared for soft tissue cutting, coagulation, and thermal ablation.
FTC	FDA product code for photodynamic therapy devices and photosensitizer light applicators (e.g., Photofrin).
GE?	High-Intensity Focused Ultrasound (HIFU) devices cleared via 510(k) and de novo classification — specific product codes vary by device (Sonablate, Ablatherm, Focal-One).

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior Authorization / Coding Note

Prior authorization required. Use prior authorization to identify proposed focal prostate ablation procedures (including but not limited to focal laser ablation, HIFU, cryoablation, RFA, photodynamic therapy, and magnetic nanoparticle–based ablation) and ensure coding matches the procedure(s) being requested (see Coding block). Providers should be aware that unlisted/proprietary codes (e.g., 55899) or newer Category III codes (e.g., 0582T, 0655T, 0738T–0739T, 0950T) may trigger additional review.

Affected codes: CPT 0582T, 0655T, 0738T, 0739T, 0950T, 55880, 55899; use of unlisted or new Category III codes will prompt review and documentation requests.
Prior authorization is required before scheduling when focal therapy is proposed as primary treatment for localized prostate cancer.

Denial Risk

Evidence- & Guideline-Based Denial Risk

Focal therapies for primary localized prostate cancer are considered investigational due to insufficient high-quality, prospective comparative evidence versus standard options (surgery, radiotherapy, or active surveillance). Guidelines (AUA/ASTRO/ASCO/SUO, NCCN) note a lack of high-quality comparative data and recommend against routine use of whole-gland or focal ablation outside clinical trials for many patients. Requests for routine primary focal ablation have a high risk of denial without documentation of trial enrollment or exceptional circumstances.

Background and Rationale

Focal therapy is intended to ablate discrete prostate cancer lesions (often targeting the index lesion) to reduce tumor burden while preserving urinary, sexual, and rectal function. Modalities discussed include focal laser ablation, HIFU, cryoablation, RFA, and photodynamic therapy. Despite promising short-term oncologic control and potentially lower adverse event rates compared with radical treatments, evidence is limited by heterogeneity, inconsistent outcome reporting, and lack of standardized patient and lesion selection, preventing conclusions that focal approaches improve long-term survival or net health outcomes.

Definitions and Key Terms

Index lesion — definition

DefinitionThe index lesion is the largest cancerous focus with the highest-grade tumor in the prostate and is considered most likely to determine clinical progression and metastasis.

Clinical rationalePathologic and molecular evidence indicates a single index tumor focus usually drives disease progression; treating the index lesion is the basis for lesion-targeted 'focal therapy'.

Size/selection noteSmall foci <0.5 cm^3 with Gleason score <7 are often left in place under the index lesion strategy as unlikely to progress over 10–20 years.

Focal laser ablation — definition

DefinitionFocal laser ablation is destruction of tissue using a focused beam of electromagnetic radiation delivered via a laser fiber introduced transperineally or transrectally into the cancer focus, producing coagulative necrosis via thermal conversion.

Policy Summary

PayerPremera Bluecross

PolicyFocal Treatments for Prostate Cancer

Policy CodePolicy MEDICAL POLICY -8.01.541

Change TypeNo material change

Effective DateMay 1, 2026

Next Review Date

SourceLink

On This Page

Guideline citation: AUA/ASTRO/ASCO/SUO 2022 — inform patients of lack of high-quality comparative data; do not recommend for high-risk patients outside trials.
NCCN (v.4.2026) — local therapies like cryotherapy or HIFU are not recommended as routine primary therapy due to lack of long-term comparative data.

Denial Risk

Regulatory Advisory Outcomes May Trigger Denial

Regulatory outcomes and FDA advisory actions may influence coverage determinations. For example, an FDA advisory committee voted against recommending approval of padeliporfin (Tookad) for localized prostate cancer over concerns that it could supplant active surveillance for very low‑risk disease; such regulatory findings may support denial of coverage when long‑term benefit is unproven.

Document any FDA advisory committee decisions or approvals relevant to the device/drug used for the proposed focal therapy.
A negative advisory recommendation or absence of FDA approval/clearance for the specific device/drug may increase likelihood of denial.

Documentation Required

Documentation Supporting Lesion Localization

Document lesion localization and histologic confirmation thoroughly. Prior authorization and medical review will require evidence that the index lesion(s) have been localized and characterized and that treatment is targeted appropriately.

Imaging: Provide multiparametric MRI (mpMRI) reports/images with PI-RADS scoring and correlation to the treated target(s).
Histology: Provide targeted biopsy pathology confirming clinically significant cancer in the index lesion (e.g., Gleason ≥3+4 where applicable) and descriptions tying biopsy cores to imaging targets.
Localization technique: Document any transperineal mapping, MRI-ultrasound fusion guidance, or other localization methods used to plan/guide the focal ablation.

Documentation Required

Trial Enrollment / Study Documentation

Enrollment in prospective clinical trials supports consideration for coverage; provide study identification and documentation of enrollment when applicable.

List trial identifiers and status (e.g., NCT numbers) in the authorization request — examples: NCT03531099, NCT03568188, NCT05010759 (NanoTherm IDE).
If the member is enrolled in an approved clinical trial, attach enrollment documentation, consent forms, and the protocol or site confirmation to the prior authorization request.

Note

Clinical Pathways and Alternatives (Active Surveillance, Whole-Gland Therapies)

Follow established clinical pathways and consider standard management options before focal therapy. For many individuals with low‑risk disease, active surveillance is the recommended approach; radical prostatectomy or external‑beam radiotherapy are standard definitive therapies when definitive treatment is chosen.

Ensure documentation discusses consideration of active surveillance for low‑risk patients and documents why surveillance is unsuitable if focal therapy is proposed.
When definitive treatment is elected, include rationale for preferring focal therapy over whole‑gland surgery or radiotherapy, and documentation of counseling on expected outcomes and toxicities of standard therapies.

Step Therapy

Stepwise Standard Therapy Preference

Follow a stepwise preference for standard, guideline‑endorsed therapies prior to focal ablation when clinically appropriate. Providers must document that patients were informed about and considered guideline‑recommended options and that focal therapy is being considered only after shared decision‑making or within a trial.

Document shared decision‑making: counseling notes detailing discussion of risks/benefits of active surveillance, radical prostatectomy, and radiotherapy versus focal therapy.
If focal therapy is requested as primary treatment, include explicit justification for deviating from standard therapies or note enrollment in a clinical trial.

Prior Authorization

Investigational Status Triggers Prior Authorization/Denial Pathways

Use of any focal therapy modality for localized prostate cancer is considered investigational per this policy and will trigger prior authorization review and potential denial unless enrollment in an appropriate clinical trial or exceptional documented circumstances are provided.

All focal modalities (laser, HIFU, cryoablation, RFA, photodynamic therapy, magnetic nanoparticle ablation, etc.) are investigational for primary localized prostate cancer under this policy.
Requests lacking trial enrollment or adequate documentation of lesion localization, patient selection justification, and informed consent for investigational therapy are likely to be denied.

Alternate termsAlso called photothermal therapy, laser interstitial therapy, or laser interstitial photocoagulation.

Imaging guidanceFocal laser ablation typically uses MRI guidance for probe placement (unlike most other focal methods which use ultrasound).

Cryoablation — definition

DefinitionCryoablation induces cell death by freezing (ice-ball formation) and vascular compromise from thrombosis and ischemia when tissue temperatures drop below -30°C, using transperineal cryoprobes placed under transrectal ultrasound guidance.

TechniquePerformed via transperineal insertion of one or more cryoprobe needles using a prostate mapping template and ultrasound guidance.

MechanismCell membrane disruption from ice crystals plus vascular thrombosis cause direct cellular toxicity and tissue necrosis.

Radiofrequency ablation (RFA) — definition

DefinitionRadiofrequency ablation (RFA) produces thermal coagulative necrosis by transmitting energy from a generator (50-watt, ~460 kHz) through multiple needle electrodes inserted transperineally under ultrasound guidance to raise tissue temperature.

Equipment/techniqueEnergy is transmitted through multiple (e.g., 15) needle electrodes placed transperineally with ultrasound guidance to target the tumor focus.

MechanismLocal tissue heating leads to coagulative necrosis of the targeted lesion.

Photodynamic therapy — definition

DefinitionPhotodynamic therapy uses an intravenous photosensitizing agent distributed in prostate tissue followed by light delivery (via transperineal needles) that induces a photochemical reaction producing reactive oxygen species and causing cell death.

Monitoring limitationReal-time monitoring of tissue effects is limited and variable optical properties of prostate tissue complicate assessment of necrosis and treatment progress.

Regulatory noteSome photosensitizing drugs and light applicators (e.g., porfimer sodium/Photofrin, psoralen) have FDA 510(k) clearance; padeliporfin (Tookad) was not recommended for FDA approval by an advisory committee in 2020.

Photodynamic agents and product codes — definition/context

Photosensitizing agentsPorfimer sodium (Photofrin) and psoralen are photosensitizers/light applicators that have been cleared by the FDA (510[k]).

FDA product codeFTC is the FDA product code referenced for photosensitizer ultraviolet lamps used in photodynamic therapy.

Regulatory contextAn FDA advisory committee voted against recommending approval of padeliporfin dipotassium (Tookad) for localized prostate cancer in 2020 due to concerns about use in very low-risk disease.

Magnetic Nanoparticles (NanoTherm) — definition and IDE study

DefinitionMagnetic nanoparticle therapy (NanoTherm) uses injected magnetic nanoparticles and an alternating magnetic field to generate local heat for tumor ablation in the prostate.

Study/IDE statusNanoTherm is being evaluated in a clinical study under an FDA Investigational Device Exemption (IDE), clinical trial identifier NCT05010759.

MechanismAlternating magnetic field activation of nanoparticles produces focal heating and local tissue ablation.